Kyverna Therapeutics Inc(NASDAQ:KYTX) 
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2024.
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.91
H 2.00
L 1.85
C 1.98
V 334,473
10EMA 1.98
20EMA 1.98
60EMA 1.98
120EMA 1.98
250EMA 1.98